Facebook
X
LinkedIn
ForwardIn this activity, there are standards of care and government mandates documentation of prognostic indicators and staging which are constantly evolving new therapeutic approaches introduced or investigated through clinical trials for cancer.
LINK:
OBJECTIVES: Upon completion of this activity, the participant should be able to:
1. Apply NCCN guidelines consistently when developing treatment plans for lung cancer patients.
2. Identify evidence-based timing for surgical intervention in metastatic cases.
3. Integrate new treatment modalities and clinical trial options into patient care.
4. Collaborate in multidisciplinary discussions to formulate optimal treatment strategies.PLANNER/MODERATOR DISCLOSURE: The planners have no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
DESIGNATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For assistance please contact: Kimberlee Martin at [email protected].